Click on a filter below to refine your search. Remove a filter to broaden your search.
The medication already was approved for advanced disease.
Once-weekly efsitora was noninferior to once-daily degludec for a decrease in the mean glycated hemoglobin level.
Black beneficiaries have lower average doses in the first 90 days.
A reduced risk for Alzheimer’s disease, vascular dementia and Parkinson’s disease was seen with SGLT2i use in type 2 diabetes.